Overview

A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study was a prospective, randomized, controlled phase III clinical study to evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine versus oxaliplatin plus capecitabine in the treatment of gastric or gastroesophageal junction adenocarcinoma with postoperative pathological stage IIIB and IIIC.
Phase:
Phase 3
Details
Lead Sponsor:
LiNing
Treatments:
Capecitabine
Docetaxel
Oxaliplatin